Clofarabine in pediatric acute leukemia: Current findings and issues
Authors:
- 21 February 2012
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (3) , 417-422
Abstract
Clofarabine is a second‐generation purine nucleoside analog and has significant anti‐leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA‐damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians. Pediatr Blood Cancer 2012;59:417–422.Keywords
This publication has 28 references indexed in Scilit:
- Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemiaBritish Journal of Haematology, 2011
- Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibitionBlood, 2010
- Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic SyndromeJournal of Clinical Oncology, 2010
- Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First CenturyJournal of Clinical Oncology, 2010
- Clofarabine, cyclophosphamide and etoposide as single‐course re‐induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemiaBritish Journal of Haematology, 2009
- A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemiaLeukemia, 2009
- Clofarabine combinations as acute myeloid leukemia salvage therapyCancer, 2008
- Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasBlood, 2007
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003